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Objectives: The terminology used to describe community participation in health technology 
assessment is contested and frequently confusing. The terms patients, consumers, public, lay 
members, customers, users, citizens and others have been variously used, sometimes 
interchangeably. Clarity in the use of terms and goals for including the different groups is 
needed to mitigate existing inconsistencies in the application of patient and public involvement 
(PPI) across HTA processes around the world.   
Methods: We drew from a range of literature sources in order to conceptualize i) an operational 
definition for the ‘public’ and other stakeholders in the context of HTA and ii) possible goals 
for their involvement. Draft definitions were tested and refined in an iterative consensus-
building process with stakeholders from around the world. 
Results: The goals, terminology, interests and roles for PPI in HTA processes were clarified. 
The research provides rationales for why the role of the public should be distinguished from 
that of patients, their families and caregivers. A definition for the public in the context of HTA 
was developed: A community member who holds the public interest and has no commercial, 
personal or professional interest in the HTA process 
Conclusions: There are two distinct aspects to the interests held by the public which should be 
explicitly included in the HTA process: the first lies in ensuring democratic accountability and 
the second in recognising the importance of including public values in decision-making.  
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It has been 50 years since Arnstein published her seminal paper, “A ladder of citizen 
participation” (1). It aimed to distinguish between citizen control and empowerment and citizen 
consultation and levels of ‘tokenism’. Some forty years later, Tritter and McCallum (2) 
published a critique of Arnstein’s model, suggesting that her emphasis on power undermined 
the potential of involvement processes. Tritter and McCallum explored the  involvement of 
users of healthcare in healthcare decision-making, focusing on aspects of effective involvement 
that Arnstein’s model did not consider (Arnstein’s “missing rungs” (2, p.161)).  
 
From ‘citizens’ to ‘users’, Tritter and McCallum’s paper reflected a neoliberal shift in citizen 
involvement to that of  “future service users” and “potential patients” (2, p.160). The shift 
emerged from  the notion that markets could improve health service provision by  “giving 
[patients] purchasing power - i.e. making them customers of primary care services” (emphasis 
in the original text) (3, p.95). The term ‘user’ employed by Tritter and McCallum (2) is 
consistent with ‘consumer’, the term preferred in Australian government circles.  
 
Debate over terminology continued.  Coulter suggested that it was “easy to stumble into 
semantic minefields when writing about patient engagement” (4, p.8), and rejected the use of 
alternative terms to ‘patient’.  However, in many countries, the term fell out of use in a context 
which saw service delivery as operating within a market. The term ‘citizen’, on the other hand, 
suggests a reciprocal arrangement with the state in which individuals have both rights and 
responsibilities.  It also carries notions of nationality and may be seen to exclude non-citizen 
residents. While the term ‘citizen’ includes patients, in recent years “public and patient” or 
simply “public” involvement has mostly engaged those presenting patient and/or carer 
perspectives. (5)  
 
Public and patient involvement in HTA and HTA-informed decision-making, at least initially, 
appears to have been undertaken with relatively little attention to the roles these groups might 
play.  Boothe suggests that, without any clear goals, the inclusion of public members in the 
Canadian Drug Expert Committee was a response to demands by patients groups “and a 
reluctance on the part of experts in agencies responsible to involve patients directly on the 
committee” (6, p.639). She also documents how our iterative engagement (7), described in this 
paper, sparked intense reflection and debate amongst researchers, agencies and patient 
communities (6) with one ministry official commenting, “they’re working on trying to make a 
conceptual distinction between patient and public…I find that really hard to draw, except at 
the extreme case” (6, p.640).  As of November 2019, there is no definition of ‘public’ provided 
in the glossary of Health Technology Assessment international (8) or HTA Glossary.net 
although there are definitions of patient, consumer, user, advocate and patient representative 
(see Table 1). In the main, the definitions describe the type of individual involved and not the 
interests that they represent.  To date, in many cases, the distinction between ‘public’ and 
‘patient’ or ‘consumer’ has failed to penetrate the working processes of HTA and HTA 
decision-making. A summary of public and patient involvement across countries is provided 
in Supplementary Table 1.  
 
Implications for health technology assessment (HTA) 
The lack of clarity in the use of these terms has resulted in their inconsistent application across 
HTA processes around the world. Health technology assessment (HTA) is a multidisciplinary 
process through which governments compare new health technologies with existing publicly 
funded medicines, services and devices. It is based on a systematic evaluation of safety, 
effectiveness, cost-effectiveness and social, ethical and legal factors. It supports decisions on 
which technologies to fund and, in some cases, which ones not to fund (9, 10).  
 
The past ten years have seen increasing demand for patient and public involvement (PPI) in 
HTA and HTA-informed policy decision-making (11, 12). This has stemmed from a broader 
move towards patient centred care in all health systems, a focus on patient empowerment and 
the associated collectivisation of patient voices in patient organisations and lobby groups (12).  
Also, a desire to address a ‘democratic deficit’ in representative democracies has emerged.  
Democratic deficit refers to a point at which the public becomes disaffected with governments 
and political matters because they are not aligned with public aspirations (13). In general, 
stakeholders, including clinicians, industry, HTA agencies and government departments, have 
responded favorably to patient involvement in HTA processes. Patient involvement supports a 
broad panel of objectives, including improved practice, transparency, legitimacy and 
comprehensiveness through the incorporation of valuable information about the ‘lived 
experience’ of patients and carers (12). However, concern remains that a focus on patient 
interests may increase pressure to publicly fund particular services, drugs and devices outside 
the usual funding criteria. Consideration of public interests – namely appropriate use of limited 
resources and preservation of a well functioning health service – can act to mitigate these 
concerns. 
 
Currently, most HTA decision making processes are based on systematic reviews of safety and 
effectiveness and an economic evaluation that generates a cost per quality adjusted life years 
(QALY) and an incremental cost effectiveness ratio (ICER). If the process reflects the values 
held by society, the use of QALYs assumes that the public and patients highly value population 
health maximisation. In most countries, however, there has been little empirical work on what 
the public values in terms of health technologies or what constitutes the public interest. Where 
this research has occurred, the public prioritised funding of technologies based on other criteria, 
namely, equitable distribution of resources, life-saving treatments, prevention and 
interventions for children (14, 15).   
 
In Australia, the Consumer Consultative Council is designed to reflect consumer rather than 
public interests. The Pharmaceutical Benefits Advisory Committee (PBAC) and Medical 
Services Advisory Committee (MSAC) processes allow and invite public input but the process 
primarily attracts submissions from patients, carers and patient advocacy groups (16). In 2006 
the Canadian Drug Expert Committee added two public members and the Ontario Committee 
to Evaluate Drugs added two patient representatives but the role of both is to collect, interpret 
and present information from patient groups (6). 
 
In the UK, through input from the Citizens Council, NICE has included a public perspective 
on broad moral and ethical issues in public health care policy sometimes at odds with economic 
imperatives (17). Recommendations from the Citizens Council are not directly incorporated 
into NICE guidance but are included in Social Value Judgement documents with which 
decisions are expected to align. The Citizens Council has examined trade-offs between equity 
and efficiency (14), and departures from the recommended ICER threshold (15). Whilst this 
has provided important community input into specific moral and ethical issues surrounding 
health funding decisions, it does not provide public input in the same way that clinician, health 
economist, and consumer advocate input is currently provided. In addition, it is unclear whether 
the general value statements are interpreted such that the final decisions would align with 
technology-specific recommendations if they were made directly by a public panel.  
 
Despite involvement of patients and the public in HTA processes for more than a decade, 
standardized methods are underdeveloped.  This has resulted in the use of the terms ‘patient’ 
and ‘public’ interchangeably in many HTA organisations. (5, 6). The lack of guidance around 
the use of terms is at odds with the traditionally rigorous standards employed in HTA to assess 
the safety, effectiveness and cost-effectiveness of health technologies (18, 19). It also 
contributes to the potential for “mismatched expectations” (5, p.96) in decision making, leaving 
PPI in the HTA process open to criticism. In addition, where this conflation occurs, public 
interests may not be explicitly included in HTA decision-making but rather they are considered 
in an ad hoc manner dependent on the inclination of those involved.  
 
This paper clarifies the goals, terminology, interests and roles for public involvement in HTA 
processes and provides a rationale for why the role of the public should be distinguished from 
that of patients, their families and caregivers.  
 
Methods 
The term, health technology assessment was used as defined in HTAGlossary.net (accessed 
November 2019) an official collaboration between the peak HTA bodies including HTA 
international and International Network of Agencies for HTA. This definition excludes 
‘decision-making’ from HTA. The decision-making step is an important point for incorporation 
of public values in funding decisions and therefore we included consideration of HTA-
informed decision-making in this work. To conceptualize an operational definition for the 
‘public’ in the context of HTA and possible goals for their involvement, we drew from i) 
literature reviews we had previously conducted on the use deliberative methods in HTA 
(See.23 & 24 in Table 2), ii) our own primary research on the inclusion of patient and public 
voices in HTA (See 16-19, 21, 22,26 & 28 in Table 2), and iii) additional relevant key scholarly 
papers identified primarily through a literature review conducted for the doctoral thesis of 
author EL and with a small number of papers offered by participants in the consultation process 
described below (See 1-15, 20, 25 & 27 in Table 2). 
 
We applied an iterative process with stakeholders over several years. Draft definitions were 
refined in consultation with academic researchers and practitioners of PPI processes in HTA, 
including members of the Health Technology Assessment International (HTAi) Patient and 
Citizen Involvement Group (PCIG) (http://www.htai.org/interest-groups/patient-and-citizen-
involvement.html). We note that initially the distinction between patient and public was highly 
contentious as some argued that all stakeholders, including patients and craft groups, were 
members of the public. A version of the document was released for consultation to the 
PCIG/HTAi working groups during the period from July to September 2016. The feedback 
received was then used to refine the list of goals for involvement and develop a nomenclature 
for different types of public in the HTA process. Subsequently, the definition and goals were 
refined at a workshop involving individuals from different stakeholder groups at the 2017 
Canadian Agency for Drugs and Technologies in Health (CADTH) Conference in Ottawa (7). 
A revised document was released to the PCIG, the workshop participants and the Australian 
public and patient engagement advocacy group, Health Technology Assessment – Australia 
(HTA-Aus), for a second round of consultation early in 2018. The final description was 




Participants in the consulted groups agreed that clearer definitions of PPI were needed. The 
rationale for patient involvement was seen as relatively well defined, (12) namely to reflect the 
patient experience of diseases and technologies used in their treatment, to ensure that patient 
priorities were considered and to support the inclusion of the views of those stakeholders who 
would be most impacted by the decisions. Clearly patients are consumers (or users) of 
technology but consumers may also be healthy individuals who undergo screening or use 
vaccines or other preventive technologies. The role of consumers in HTA is very similar to 
those of patients, namely to reflect the consumer experience with these technologies and to 
support the inclusion of consumer views in decision-making. Goals for public involvement, 
who constitutes the public, the nature of public interests and the lines of separation between 
public and patient and consumer interests were seen as much less well defined. Participants 
described six possible goals for public involvement in HTA. 
 
The goals and rationale for ‘public’ involvement 
 
The goals for including the public are shown in Table 3. 
 
The rationale for these goals is as follows: 
  
 1. To improve the comprehensiveness of evidence underpinning the decision-making for 
individual health technologies 
 
The public may offer important insights into the value proposition of specific public health 
related technologies, such as vaccines or health promotion and screening programmes. They 
may also help to ensure that technologies which elicit strongly held social and cultural values, 
such as contraceptives or assisted reproductive technologies (20) or those being considered 
for  disinvestment  (21) are assessed as holistically as possible. 
 
2. To increase the legitimacy of the process for the assessment of preventive technologies, 
thereby ensuring public uptake of the findings 
 
The public utilise preventive technologies; vaccines are an important aspect of public health, 
which is threatened by concerns about their safety. Similarly, doubts about the effectiveness of 
some screening programs impact their uptake (22). Greater public involvement in HTA 
processes, with associated improved public understanding, may increase legitimacy, allay 
community fears and improve uptake.  
  
3. To increase the capacity of the public to engage in their own health care 
 
Health literacy and public understanding of the assessment of new technologies may be 
improved by making the process of HTA more accessible to the public and more transparent.  
A more ‘health literate’ public is a public more likely to become informed about their own 
health care: this is an essential plank for improving population health and building support for 
public health measures. 
 
4. To improve involvement of members of the public in the democratic process  
 
Over the past 20-30 years, there has been demand for a more devolved participatory democracy 
in developed nations.  The drivers for this demand include increased availability of evidence 
to all (23), the rise of social media with national and global public discussion of policies (24), 
falling trust in governments (25) and the recognised ‘weaknesses in traditional representative 
structures” (26, p.22). Loss of trust in governments and representative democracy is 
particularly evident in younger voters. (27) Public participation in policy development and 
decision-making  processes have high levels of support amongst younger voters and could be 
seen as a mechanism for  overcoming some of the weaknesses in representative democracy, 
where voting is usually around a “limited set of choices with little depth of involvement” (26, 
p.22). Some governments are now including deliberative informed public involvement 
processes in specific cases where decision making is contentious (for example, 28).  
 
5. To ensure that the HTA process aligns with public values and that the interests of the public 
are included in the HTA process 
 
Values are intangible standards or principles which guide our choices and behavioural 
responses and provide meaning to our lives. These might include personal Kantian virtues 
such as good will and moral duty. At the societal level such virtues underpin public values of 
fairness, accountability and integrity. Public values are typically elicited through empirical 
research (e.g., citizens’ juries).   
 
Interests embody the trade-offs we are willing to make in the execution of those values. For 
example, many people believe autonomy and respect for personal privacy should be 
underpinning values guiding government processes and decision-making. The public interest 
therefore lies in ensuring that the HTA processes and the subsequent decision-making reflect 
respect for persons. This invariably requires trade-offs with other values. For example, the high 
public value placed on health and wellbeing and effective health services may require some 
loss of a privacy and autonomy due to sharing of health data. How trade-offs should play out 
in HTA processes is difficult to decide if we do not understand the range of values held by the 
public and the weightings the public would make in trading one against the other.  
 
In deliberations determining public values and interests or in representation of those interests, 
individuals should come to the deliberation as free as possible from other interests. Although 
others involved in the HTA process are also members of the public, they represent specific 
interests, including those of patients, healthcare providers, health administrators, industry and 
public services. They are often appointed to committees because of their affiliation with those 
groups through their work, professional role and qualifications. The inclusion of members of 
the public, without particular financial, work or personal interests in the outcome, in these 
committees ensures broader representation in decision making and explicit consideration of 
public interests. In some cases, active inclusion of the public interest may act as a bulwark 
against powerful vested interests wishing to undermine the rigour, impartiality and 
independence of the HTA process.   
 
6. To assist in explaining to the public the rationale for difficult decisions which deny funding 
for potentially life-saving or life-altering health technologies 
 
Funding for contentious health technologies which loom large in the public imagination but 
fail to measure up in the assessment processes are an ongoing issue for governments (for 
example, see 29). In acting as independent advocates for the public interest, public panels or 
public members present the public interest argument for denying or approving public funding 
for technologies which are considered overly expensive relative to public benefit or for which 
evidence of benefit is equivocal. This is an extension of goals 5 and 6 in that, under these 
circumstances, PPI acts as a conduit for public education and informed debate but also as a 
process for formal input on public interests and values. 
 
Defining terminology for ‘the public’ in HTA and HTA-informed decision-making 
 
In Table 4, we define terms which have been loosely defined and often used interchangeably 
in the HTA community. These terms were developed from scholarly literature and in 
consultation with a broad group of members of the HTAi community, but we suggest that there 
is no right or wrong definition. The actual term used is less important than achieving consensus 
from the HTA community about what the terms mean. In other areas of HTA, there is a clearly 
understood shared language.  
 
In the consultation process, our original definition of public, drawn from the literature, was 
expanded to describe particular exclusions such as those individuals representing commercial 
industries manufacturing drugs and devices, the HTA industry and individuals who work or 
who have previously worked in the health care industry. In addition, we excluded individuals 
with personal interests from this term, including patients and carers, so as to be consistent about 
the inclusion of the public interest. Other definitions were also refined in response to feedback. 
For example, our original definition described a patient as someone ‘with a diagnosed disease 
or disorder’. As a result of the consultation the word ‘diagnosed’ was dropped as being too 
narrow and the sentence: “An individual with the lived experience of a disease or disorder who 
can provide information pertinent to that disease or disorder” added in order to describe the 
contribution such a person might bring to the HTA process. The term ‘representative’ was 
removed and the word ‘represent’ used carefully since the capacity or remit for a person to 
‘represent’ patients or the public was seen as problematic.  Therefore, the word was only used 
to describe individuals who were consumer or patient advocates and thus specifically asked to 
represent the views of others. Finally, we recommend against the use of the term ‘lay’. 
Although considered a neutral term by some (30), in the context of HTA decision-making, 
where we are making the case for public and patient expertise, it is damaging: for example, 




Fifty years after Arnstein’s ladder of citizen participation (1) and 13 years after Tritter and 
McCallum’s work on user involvement (2), the conceptualisation of public involvement in 
public decision-making has shifted. Arnstein’s ladder reflected the paternalistic and rigid 
processes of the sixties and the contemporary push for more participatory processes and ‘citizen 
power’. Tritter and McCallum’s reformulation reflected the rise of patient-centred care, the 
empowered patient and advocacy for patient involvement in those decisions which affected 
them. By 2007, it was clearly problematic to ask patients to manage their own care while 
denying them any input into the very decisions which affected the range of health technologies 
to which they had access. The latest iteration in this debate, which we describe in this paper, is 
a recognition that patients and the public hold very different interests and both sets of interests 
should be systematically incorporated into public decision-making.  
 
It is difficult to comment on differences between the public and patient populations in terms of 
their held values since there is little empirical evidence drawing this comparison. There is some 
evidence that even where values are shared they may be differently weighted, for example, 
some studies suggest that patients have a higher tolerance of risk than the public (31). However,  
as the findings from this article and Boothe (6) suggest, the interests of patients, patient 
advocates and patient members lie primarily in advocating for specific medicines or treatments 
which will benefit a particular patient group whereas the interests of the public will always rest 
not only in ensuring equitable distribution of scarce resources amongst all patient groups  but 
also in supporting a well-functioning society which sustains the wellbeing of all. Further, the 
goals of PPI described in this paper go well beyond the instrumental goals which might be met 
through observing changed recommendations from an advisory committee or an altered final 
funding decision as a result of PPI (6). This narrow understanding of the potential impact of 
PPI neglects the benefits of a more transparent and inclusive process particularly in democratic 
accountability and in maintaining and rebuilding public trust in government decision-making 
(6). More empirical research is needed to explore whether increased public and patient 
involvement increases public trust in the HTA process.  
 
The ways in which Australia, Canada and the UK conceptualise public and patient engagement 
in HTA processes, described in the introduction to this paper, exemplify one way of 
differentiating the roles of patients/consumers and the public. This was identified by 
Fredriksson (5) as patient and consumer views drawing on “experiential knowledge generated 
from being a service user” and public views, exemplified by the UK NICE Citizens Council, 
as “collective perspectives generated from diversity”(5, p.97). Our work points to a different 
interpretation: the terms describing patient and public in HTA should not describe who the 
people are but rather the interests and values they are tasked to present in the HTA process or 
at the decision-making table.  
 
Arising from the public involvement goals described in this paper, our work suggests that there 
are two distinct aspects to the interests held by the public which should be explicitly included 
in the HTA process. The first lies in ensuring democratic accountability in the process, namely 
that it includes comprehensive, high-quality evidence, good deliberation and is free from  bias 
from special interests. In this role,  public members act as independent auditors for the process, 
building legitimacy and public trust for the process. The second ensures the inclusion of public 
values. These values would need to be delineated in diverse informed deliberative fora. The 
role of a deliberative public council might be to develop a generic set of values similar to the 
operation of the NICE Citizens Council with explicit inclusion of these values in the process. 
For example, individuals from the council might sit on any decision making body or be 
embedded in the HTA process. Alternatively, contentious decisions in HTA could be directly 
considered by a public council. The ways in which the public values and interests are explicitly 
included in HTA and the HTA-decision making process will need to be developed within each 
jurisdiction to reflect the particular policy context. Potentially public representation could act 
as a broker between the broader public and the decision making committee, assisting in 




Including the public and patients in HTA and HTA-informed policy decisions has become an 
imperative in many jurisdictions using HTA as the basis for government health care provision. 
However, their inclusion has been compromised by the lack of clarity around goals and the 
roles of the public and patients. This paper provides definitions of those goals and roles drawn 
from the literature and shaped in a consensus building process. The definitions provided here 
are particular to the HTA context, but may also be useful in other areas where patients and the 
public are included in decision making. The next step is a broader discussion across all HTA 
stakeholders in order to provide an industry-wide understanding of the distinct roles and 
interests of patient and public members in the HTA process.  
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Table 1: Definitions in common usage in HTA  
 Definition provided by HTAGlossary.net * Definition provided by Glossary for Consumers and 
Patients, HTAi Patient and Citizen Involvement  




No definition provided No definition provided 
patient A person, presenting with clinical signs or not, who consults a 
physician. See consumer 
 
See consumer 
consumer A person who uses, is affected by, is entitled to or is compelled to 
use a health service.  
Note: In the health care field, the term consumer is used mainly in 
the United States, where there is no universal health insurance 
system. Elsewhere ‘patient’ is often used, but since this word 
should be applied only to persons who consult a physician, terms 
such as user, recipient and client are used in the Canadian health 
system. Syn.: patient, user, recipient, client  
A person who is the ultimate user of the health care 
resource. A consumer may or may not have a specific 
health issue, condition or disease. A patient is someone 
with a specific health condition. All  patients are 
consumers, but not all consumers are patients 
user See consumer and patient No definition provided 
Carer / care 
giver 
 
1) A duly trained and paid person who provides a person with a 
disease or disability with care.  
2) A person (often a family member or friend), paid or unpaid, 
who regularly provides a person with a disease or disability with 
any form of care.  
A person who looks after family, partners or friends in 
need of help because they are ill, frail or have a 
disability. The care they provide is unpaid.  
 
lay No definition provided No definition provided 
stakeholder No definition provided No definition provided 
consumer 
representative 
A person or organisation who/that is actively involved with others 
and presents the perspectives and concerns of a group of patients. 
Syn.: patient representative. 
No definition provided 
consumer 
advocate 
No definition provided See advocate:  
Advocate: Someone who speaks on behalf of themself or 
another person.  In health, an advocate is usually a person 
who speaks on behalf of a health care consumer or patient, 
or a group of consumers or patients. An example of an 
advocate is a person who is closely  involved with 
consumers or patients or a consumer support group,  and is 





See consumer advocate. 
 





No definition provided No definition provided 
*Accessed November 2019 
  
Table 2: Literature used to support the development of an operational definition for the ‘public’ in the context of HTA and possible 
goals for their involvement, 
 
# Reference Contribution to concept development 
1 Abels G. Citizen involvement in public policy-making: does it 
improve democratic legitimacy and accountability? The case of 
pTA. Interdisciplinary Information Sciences. 2007; 13(1):103-
16. 
 
Describes the normative claims for citizen participation. 
Distinguishes between the scientific assessment of new 
technologies and the normative evaluation of their impact. Critiques 
and explores the functions, goals and models of participatory 
technology assessment.  
 
2 Abelson J, Giacomini M, Lehoux P, Gauvin FP. Bringing 'the 
public' into health technology assessment and coverage policy 
decisions: From principles to practice. Health Policy. 2007; 
82(1):37-50. 
 
Explores questions of which publics to involve and the goals of 
public engagement in health technology assessment. In particular 
distinguishes between process-oriented goals and instrumental 
goals for this involvement.  
 
3 Abelson J, Wagner F, DeJean D, Boesveld S, Gauvin F-P, Bean 
S, Axler R, Petersen S, Baidoobonso S, Pron G, Giacomini M, 
Lavis J. Public and patient involvement in health technology 
assessment: A framework for action.  
Collates the international HTA practice of patient and public 
involvement (PPI) in HTA agencies extracting the goals and 
rationales for PPI. Distinguishes between patients, the public and 
other stakeholders, advocates the establishment of a common 
language to support PPI and suggests the different groups should be 
involved at different stages in the HTA process.  
 
4 Anderson W, Florin D, Gillam S, Mountford L. Every Voice 
Counts: Primary Care Organisations and Public Involvement. 
London: The Kings Fund; 2002. 
 
A case study of the development of public involvement structures 
in six UK primary health care organisations and in particular the 
meaningful inclusion of public voices in decision-making. Includes 
the value and goals of public involvement and the some of the issues 
encountered in developing participatory processes. Critiques 
Arnstein’s Ladder as a framework.  
 
5 Barham L. Public and Patient Involvement at the UK National 
Institute for Health and Clinical Excellence. Patient. 
2011;4(1):1-10. 
Describes and critiques the involvement of patients and public 
members in NICE processes.  
 
6 Bombard Y, Abelson J, Simeonov D, Gauvin FP. Eliciting 
ethical and social values in Health Technology Assessment: a 
participatory approach. Social science & medicine. 
2011;73(1):135-44. 
 
Describes a Canadian empirical deliberative process eliciting the 
ethical and social values which should be considered in every 
assessment of a technology 
7 Degeling C, Carter SM, Rychetnik L. Which public and why 
deliberate? A scoping review of public deliberation in public 
health and health policy research. Social science & medicine. 
2015;131(0):114-21. 
 
Distinguishes between different publics, particularly citizens, 
consumers and advocates, their roles and the strengths that each 
bring to the process of public deliberation.  
 
8 Degeling C, Rychetnik L, Street J, Thomas R, Carter S. 
Influencing health policy through public deliberation: Lessons 
learned from two decades of Citizens'/community juries. Soc Sci 
Med. 2017;179:166-71. 
 
Discusses the ways in which the public is framed in public 
deliberation, critiques claims of representativeness and the value of 
public deliberation in policy decision making.  
9 Fredriksson M, Tritter JQ. Disentangling patient and public 
involvement in healthcare decisions: why the difference matters. 
Sociology of Health & Illness. 2017;39(1):95-111. 
 
Distinguishes between patients and citizens in community 
involvement in health care decisions and describes the slippage in 
the way in which the terms have been used. Highlights the interests 
of patients versus citizens  and the different perspectives, goals and 
benefits each brings to decision making.  
 
10 Gagnon MP, Desmartis M, Lepage-Savary D, Gagnon J, St-
Pierre M, Rhainds M, et al. Introducing patients' and the public's 
perspectives to Health Technology Assessment: a systematic 
review of international experiences. International Journal of 
Technology Assessment in Health Care. 2011;27(1):31-42. 
 
Systematic review of studies reporting participation of patient and 
public in the HTA process and the limited roles that they fulfil.  
11 Gauvin F-P, Abelson J, Giacomini M, Eyles J, Lavis J. "It all 
depends": Conceptualising public involvement inthe context of 
health technologies assessment agencies. Social science & 
medicine. 2010;70:1518-26. 
Conceptualises public involvement in the context of HTA. 
Examines how public involvement  is constructed in HTA and how 
the rationale for public involvement may conflict with HTA  
 narrowly defined (i.e. a focus on effectiveness, safety and cost 
effectiveness).  
12 Gauvin F, Abelson J, Lavis J. Evidence brief: strengthening 
public and patient engagement in health technology assessment. 
Ontario, Hamilton, Canada: McMaster Health Forum; 2015. 
 
Defines patients, the public and stakeholders and describes the 
theorized goals of public and patient engagement in HTA 
13 Guttman N. Bringing the mountain to the public: Dilemmas and 
contradictions in the procedures of public deliberation initiatives 
that aim to get "ordinary citizens"to deliberate policy issues. 
Communication Theory. 2007;17(4):411-38. 
 
Discusses the theoretical and pragmatic issues in involving ordinary 
citizens in public deliberation on policy issues. Defines the goals 
and benefits of public deliberation and normative concerns in public 
participation initiatives. Explores the potential clash between 
normative and instrumental goals in public deliberation.   
 
14 Jorgensen TB, Bozeman B. Public values: an inventory. 
Administration and Society. 2007;39;354-381 
This paper attempts to elicit the boundaries and meanings of public 
values  and the public interest from relevant literature primarily 
drawn from the area of public administration 
 
15 Lehoux P, Daudelin G, Abelson J. The unbearable lightness of 
citizens within public deliberation processes. Soc Sci Med. 
2012;74(12):1843-50. 
 
Challenges the notion of the ‘ordinary’ citizen. Explores the 
complexity and richness of the contribution of four individual 
citizens within a public deliberation process. 
16 Lopes E, Carter D, Street J. Power relations and contrasting 
conceptions of evidence in patient-involvement processes used 
to inform health funding decisions in Australia. Social Science 
& Medicine. 2015;135(0):84-91. 
 
Examines beliefs about the role of patients and public in HTA and 
hence what Australian Advisory Committee members consider to 
be reliable information to inform the HTA process.  
17 Lopes E, Street J, Carter D, Merlin T. Involving patients in health 
technology funding decisions: stakeholder perspectives on 
processes used in Australia. Health Expectations. 
2016.;19(2):331-44. 
 
Explores the idea of representativeness in HTA and the inadequate 
explication of the role (task) of patients and patient input in HTA 
processes in Australia at the time.  
18 Menon D, Stafinski T. Role of patient and public participation in 
health technology assessment and coverage decisions. Expert 
Rev Pharm Out. 2011;11(1):75-89. 
 
Sets out potential roles for patients and the public in HTA. 
Distinguishes between the roles that patients and public can fulfil 
and suggests that they be considered separately when they are 
involved in HTA 
 
19 Merlin T, Street J, Holton C, Mundy L, Tamblyn D, Juneja V, et 
al. Review of MBS items for specific ophthalmology services 
under the MBS Quality Framework. For consideration by 
Medical Services Advisory Committee. Canberra, ACT: 
Commonwealth of Australia; 2011. 
 
Using social media extracts public and patient views on the use of 
selected health technologies. This process demonstrated the 
different functions these two groups bring to HTA. 
20 Nabatchi T. Putting the public back in public values research: 
Designing public participation to identify and respond to public 
values.  The Copenhagen Public Value Consortium Biennial 
Workshop 2010 - Heterogeneity and convergence in public 
values research; Leiden, The NetherlandsJune 10-12 2010. 
 
Explores the nature of public values and provides a framework of 
goals for public participation corresponding to a spectrum of 
participation.  
21 Ploug-Hansen H, Street J. Reflections on terms, goals and 
organisation. In: Facey K, Ploug-Hansen H, Single A, editors. 
Patient Involvement in Health Technology Assessment. Berlin: 
Springer; 2017. p. 31-42. 
 
Discusses the interests held by patients including patients as a group 
across the disease spectrum. Sets out the terms used to describe 
patients in HTA and how these terms define the type of participant 
included in the process and the goals (implicit, explicit or indefinite) 
which underpin their inclusion/exclusion.  
 
22 Stafinski T, Menon D. Explicating social values for resource 
allocation decisions on new cancer technologies: We, the jury, 
find⋯. Journal of Cancer Policy. 2017;14:5-10. 
 
Uses citizens juries (Canadian)  to generate social value statements 
demonstrating consistency in the findings across juries.  
23 Street J, Duszynski K, Krawczyk S, Braunack-Mayer A. The use 
of citizens' juries in health policy decision-making: a systematic 
review. Social science & medicine. 2014;109 C:1-9. 
 
Examines the ways in which publics have been selected for citizens 
juries for health policy decision-making. Critiques the use of the 
term citizen in juries and how well juries support “active” 
citizenship.  
24 Street J, Lopes E. Deliberative methods to involve patients in 
HTA. In: Facey K, Ploug-Hansen H, Single A, editors. Patient 
Involvement in Health Technology Assessment. Berlin: 
Springer; 2017. p. 165-74. 
 
Examines the nature of deliberation in HTA and those factors which 
contribute to good deliberation. Distinguishes between patients and 
the public. Maps current potential stakeholders in HTA 
deliberations and the interest that they hold. 
 
25 Whitty JA. An international survey of the public engagement 
practices of Health Technology Assessment organizations. 
Value in Health. 2013;16(1):155-63. 
 
Documents international practice in public and patient engagement 
in HTA organisations.  
26 Wortley S, Street J, Lipworth W, Howard K. What factors 
determine the choice of public engagement undertaken by health 
technology assessment decision-making organizations? J Health 
Organ Manag. 2016;30(6):872-90. 
24.  
 
Describes the factors - and hence the underpinning goals  - which 
determine the choice of public engagement in HTA organisations. 
Distinguishes between different types of public.  
27 Wortley S, Tong A, Howard K. Community views and 
perspectives on public engagement in health technology 
assessment decision making. Aust Health Rev. 2017;41(1):68-74 
 
Provides community views on public and patient engagement in 
HTA in Australia. The findings indicate potential goals for the 
inclusion of publics including patients or consumers. 
28 Young A, Menon D, Street J, Al-Hertani W, Stafinski T. 
Engagement of Canadian Patients with Rare Diseases and Their 
Families in the Lifecycle of Therapy: A Qualitative Study. The 
patient. 2018:1-7. 
 
Explores the role of patients with rare diseases in the orphan drug 
lifecycle.  
  
Table 3. Goals for public involvement in HTA 
 
 
1. To improve the comprehensiveness of evidence underpinning the decision-making for 
individual health technologies 
 
 
2. To increase the legitimacy of the process for the assessment of preventive 
technologies, thereby ensuring public uptake of the findings 
 
 
3. To increase the capacity of the public to engage in their own health care 
 
 
4.  To improve involvement of members of the public in the democratic process 
 
 
5. To ensure that the HTA process aligns with public values and that the interests of the 
public are included in the HTA process values 
 
 
6. To assist in explaining to the public the rationale for difficult decisions which deny 




Table 4.   Definitions of terms for use in public and patient involvement in the context of Health Technology Assessment and decision making 
Term Definition and rationale 
Public 
 
A community member who holds the public interest and has no commercial, personal or professional interest in the HTA 
process 
 
Rationale: Public is an umbrella term which, in the context of the HTA process, incorporates all non-patient, non-commercial and non-
professional stakeholders within the health sector. This would exclude patients and carers and representatives from patient and 
consumer organisations since in the context of HTA they will invariably hold different interests to those of the society at large and it 
is important that these perspectives are kept separate. It will also exclude representatives from commercial vendors of drugs and 
devices and organisations offering paid health services; individuals engaged in the Health Technology Assessment industry; and 
individuals who work or who have worked in the healthcare industry. These individuals are excluded from the term because they have 
a potential conflict of interest and already have a defined role in the HTA process. The term ‘public’ would include individuals with 




An individual with a disease or disorder who is using some aspect(s) of the healthcare system because of this disease or disorder.  
 
Rationale: Patients are individuals with the lived experience of a disease or disorder who can provide information in the HTA process 




An individual who uses, has used or intends to use a particular health technology or service.  
 
Rationale: A consumer may be a patient but may also be a user of a preventive health technology e.g. screening or vaccination. The 
word consumer might also been seen to include health workers and professional and non-professional caregivers since all of these use 
technologies and therefore are consumers with the capacity to inform the HTA process. However, in the context of the HTA process 
we would exclude professional consumers from this category since they are represented in the process in their capacity as clinical 
stakeholders. We note that there is often conflation between the term consumer and patient in healthcare settings in that a healthy 




An individual who is the unpaid informal primary or secondary caregiver for a patient.  
 
Rationale: A carer or caregiver is usually recognised as holding the interests of the patient(s) in their care but may have additional 
needs and interests. In context of the HTA process, unless otherwise specified, the carer is assumed to be non-professional. 
 
Lay 
An individual who has no professional healthcare qualifications or expert healthcare knowledge.  
 
Rationale: Since all individuals have expert knowledge of their own lived experience, we suggest that this term should not be used to 
describe the patient or the public in the HTA process. In addition, we recognise that many individuals who act as patient or public 




An individual with an interest in the outcome of the HTA process final decision. 
 
Rationale: A stakeholder is someone who will be impacted i) through a change in health or lifestyle, ii) financially or iii) in some other 
way, by the decision to exclude or include a technology from public support Potential stakeholders in Health Technology Assessment 
include patients, consumers, carers, industry representatives,  
healthcare providers, employers, health insurers and other payers who are impacted by decisions made in response to the assessment. 
Members of the public and taxpayers may also be considered to be distal stakeholders in the HTA process because of their interest in 




An individual who represents and advocates for the interests of a particular group of patients on a committee e.g. patients with 
breast cancer. 
 
Rationale: We have distinguished a patient advocate from a patient member since a patient advocate is directly charged with 




An individual who has been selected to support the inclusion of the interests of the society at large on a decision-making 
committee in HTA. 
 
Rationale: We recognise that society has an interest in maintaining an efficient, effective and equitable health service which, as far as 
possible, meets the needs of all individuals in society including balancing the range of needs of patients using the system. The use of 
the word ‘partner’, for example, a public partner, suggests the member holds more power than is usually the case. We suggest the term 
‘public partner’ should be avoided. The public member may sit on a cross-disciplinary panel of HTA stakeholders (e.g. industry 





An individual who has been selected to support the inclusion of the interests of patients in Health Technology Assessment 
processes on a committee.  
 
Rationale: We recognise that patients have unique information relevant to inform the HTA process. Representation of this information 
on decision making committees is important. This individual may be a patient or an unpaid caregiver and may collate the experiences 





An individual who has been selected to support the inclusion of the interests of consumers on a committee. 
 
Rationale: we have included this term since it is used in some HTA jurisdictions e.g. Australia and, based on the definition of consumer, 
we see the remit of the member as wider than the remit of a patient member 
 
 
Supplementary Table 1: Public and patient involvement  in HTA and HTA-decision making  
Country Organization 
Specifications 





























No role identified 







• Part of advisory 
panel who defines 
scope of appraisal: 
patients 









No role identified No role identified No role identified No role identified 
Canada Canadian 




No role identified • Submit information 
to group preparing 
evaluation report: 
patients and patient 
organizations 













No role identified 
Supplementary Table 1: Public and patient involvement  in HTA and HTA-decision making  
Country Organization 
Specifications 















No role identified No role identified No role identified No role identified 









• Participate in 
defining scope of the 
appraisal: patients 
• Participate in 
consultations during 
evaluation: patients 











No role identified 
Germany Federal Joint 
Committee (G-
BA) 
No role identified • Participate in 
defining scope of the 
appraisal: patients 
• Comment on draft 
protocol for 
evaluation:  anyone 
• Submit information 








No role identified 
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Italy Italian Medicines 
Agency 
No role identified No role identified No role identified No role identified 
Japan Drug Pricing 
Organization 
No role identified No role identified No role identified No role identified 
New Zealand Pharmaceutical 
Management 









• Submit information 




















No role identified 
Singapore Singapore 
Ministry of Health 
Drug Advisory 
Committee 
No role identified No role identified No role identified No role identified 
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No role identified No role identified No role identified No role identified 
Spain National Health 
System Inter-
territorial Council 
No role identified No role identified No role identified No role identified 































patients and the 
general public 
• Participate in 
defining scope of the 
appraisal: patient 
organizations 
• Submit information 
to group preparing 
evaluation report: 
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• Comment on draft 
recommendations: 
public and patients 








• Submit information 
to group preparing 
evaluation report: 
anyone 
• Membership on 
advisory 
committee:  patient 
representative 
• Submit additional 
information: 
anyone 
• Present to 
advisory 












• Membership on 
advisory 
committee:  patient 
representative 
• Attend committee 
meeting: public and 
patients 
 
 
